ASCO 2019: Isatuximab Updates with Dr. Paul Richardson
Isatuximab is a new monoclonal antibody targeting CD38 that has been progressing through clinical trials in order to receive FDA approval. Dr. Paul Richardson joined the Myeloma Crowd at the recent ASCO 2019 conference to share the presented results from the Phase III ICARIA-MM trial. According to Dr. Richardson, although this